Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis
- PMID: 11291106
- PMCID: PMC6807797
- DOI: 10.1002/jcla.2
Plasma and urinary endothelin-1 in focal segmental glomerulosclerosis
Abstract
The kidney is an important site of endothelin-1 (ET-1) production and is particularly susceptible to ET-1 action. Infusion of ET-1 in rats induces both functional and morphological alterations in the kidneys. Increased plasma level of ET-1 has been reported in patients with chronic renal failure. However, there are still no reports on the plasma and urinary ET-1 levels in patients with focal segmental glomerulosclerosis (FSGS). In the present study, we have measured the plasma concentration and urinary excretion rate of ET-1 in 15 patients with nephrotic syndrome due to FSGS, and observed the serial changes of plasma and urinary ET-1 in nephrotic rats with FSGS, induced by repeated injection with puromycin aminonucleoside (PAN). ET-1 was measured with radioimmunoassay. The results showed that plasma ET-1 concentration in FSGS patients was significantly higher than in normal controls (P < 0.05), and that urinary ET-1 excretion rate was also significantly higher in FSGS patients than in normal controls (P < 0.01). In FSGS patients, the plasma and urinary ET-1 was significantly correlated (P < 0.05), and the urinary ET-1 excretion rate was significantly correlated with the amount of proteinuria (P < 0.05) and the glomerular sclerosing score (P < 0.01). In the ten rats with PAN-induced FSGS, serial examination showed a significant increase in plasma ET-1 after 8 weeks of injections, while the urinary ET-1 excretion rate showed a biphasic increase that showed a peak after 4 to 6 weeks. The same changes in plasma and urinary ET-1 levels were not observed in control rats injected with normal saline at the same frequency. Our results suggest that ET-1 may be involved in the pathogenesis of FSGS in both humans and rats.
Similar articles
-
Reduced podocyte expression of alpha3beta1 integrins and podocyte depletion in patients with primary focal segmental glomerulosclerosis and chronic PAN-treated rats.J Lab Clin Med. 2006 Feb;147(2):74-82. doi: 10.1016/j.lab.2005.08.011. J Lab Clin Med. 2006. PMID: 16459165
-
Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.BMC Nephrol. 2020 Jun 15;21(1):226. doi: 10.1186/s12882-020-01879-6. BMC Nephrol. 2020. PMID: 32539845 Free PMC article.
-
Experimental focal segmental glomerulosclerosis: correlation with protein excretion, glomerular filtration rate, and renal plasma flow.Pediatr Res. 1984 Nov;18(11):1195-201. doi: 10.1203/00006450-198411000-00029. Pediatr Res. 1984. PMID: 6514447
-
Secondary Focal Segmental Glomerulosclerosis: From Podocyte Injury to Glomerulosclerosis.Biomed Res Int. 2016;2016:1630365. doi: 10.1155/2016/1630365. Epub 2016 Mar 21. Biomed Res Int. 2016. PMID: 27088082 Free PMC article. Review.
-
Humoral permeability factors in the nephrotic syndrome: a compendium and prospectus.J Nephrol. 2001 Nov-Dec;14 Suppl 4:S48-50. J Nephrol. 2001. PMID: 11798145 Review.
Cited by
-
Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis.J Clin Invest. 2014 Apr;124(4):1608-21. doi: 10.1172/JCI71195. Epub 2014 Mar 3. J Clin Invest. 2014. PMID: 24590287 Free PMC article.
-
Endothelial Endothelin Receptor A Expression Is Associated With Podocyte Injury and Oxidative Stress in Patients With Focal Segmental Glomerulosclerosis.Kidney Int Rep. 2021 Apr 22;6(7):1939-1948. doi: 10.1016/j.ekir.2021.04.013. eCollection 2021 Jul. Kidney Int Rep. 2021. PMID: 34307988 Free PMC article.
-
Evaluation of Urinary Big Endothelin-1 in Feline Spontaneous CKD.Animals (Basel). 2020 Nov 18;10(11):2144. doi: 10.3390/ani10112144. Animals (Basel). 2020. PMID: 33217985 Free PMC article.
-
Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition.Pediatr Nephrol. 2021 Apr;36(4):763-775. doi: 10.1007/s00467-020-04518-2. Epub 2020 Mar 17. Pediatr Nephrol. 2021. PMID: 32185491 Review.
-
Endothelin receptor antagonists in chronic kidney disease.Nat Rev Nephrol. 2025 Mar;21(3):175-188. doi: 10.1038/s41581-024-00908-z. Epub 2024 Dec 6. Nat Rev Nephrol. 2025. PMID: 39643698 Review.
References
-
- Yanagisawa M, Kurihara H, Kimura S. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415. - PubMed
-
- Kohan DE. 1998. Angiotensin II and endothelin in chronic glomerulonephritis. Kidney Int 54:646–647. - PubMed
-
- Herman WH, Emancipator SN, Rhoten RLP, Simonson MS. 1998. Vascular and glomerular expression of endothelin‐1 in normal human kidney. Am J Physiol 275:F8–F17. - PubMed
-
- Brochu E, Lacasse S, Moreau C, et al. 1999. Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant 14:1881–1888. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources